Bevacizumab Against Recurrent Retinal Detachment

Completed · Phase 2

Conditions studied: Retinal Detachment, Proliferative Vitreoretinopathy

In brief

The investigators hypothesize that bevacizumab instilled into the vitreous after primary retinal detachment surgery will reduce the formation of proliferative vitreoretinopathy and subsequent retinal re-detachment.

Key facts

Study ID

NCT02192970

Run by

University of Wisconsin, Madison

People needed

101

Starts

2015-01-21

Expected to finish

2019-11-11

Last updated by the study team

2021-03-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Eyes with rhegmatogenous retinal detachment

You may not qualify if…

• Presence of PVR
• Need for a procedure other than primary PPV such as a scleral buckle with or without PPV, laser retinopexy, or pneumatic retinopexy.
• Recent intravitreal injection of an anti-VEGF agent less than 3 months prior
• Secondary retinal detachment repair
• Use of silicone oil as tamponade agent
• Patients less than 18 years of age
• Pregnancy
• Known allergy or contraindication to intravitreal bevacizumab

Where it is running

• University of Wisconsin — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.